Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (OTC: HALB) generates a steady stream of news centered on its healthcare technology initiatives, research collaborations, and funding developments. Investors and observers following HALB news can expect updates on traumatic brain injury (TBI) research, PTSD and mental health programs, AI-driven behavioral platforms, and partnerships with medical and technology organizations.
Recent press releases highlight Halberd’s work with Mississippi State University on a proprietary nasal spray intended to mitigate the effects of TBI, including plans for advanced Phase-2 animal studies. News items also cover the company’s acquisition and development of NeuroSense AI, a behavioral intelligence platform that combines ultrasonic vocalization analysis, micro-movement tracking, and social behavior monitoring with Claude AI-powered interpretation for preclinical TBI and neurological research.
Another major theme in HALB news is its LDX and WatchDawg programs for PTSD, suicidal ideation, and related mental health challenges, particularly among veterans. Halberd and its partners report pilot study results using LDX-based therapies, nutraceuticals, yoga and meditation, and continuous wearable monitoring via Athena GTX’s technology. Announcements describe plans for larger clinical studies, solicitations for nephrologists and clinicians, and cooperative efforts with Athena Telemedicine Partners, LLC.
News releases also discuss funding and contract developments, including a substantial contract commitment involving Defense Atomics Corporation to support combined CRISPR/nanotechnology stem cell treatment with Halberd’s LDX protocol and WatchDawg monitoring. Readers of HALB news can use this page to follow progress on government contract proposals, private investment efforts, regulatory planning, and technical milestones in AI-powered healthcare platforms.
For anyone tracking HALB stock or its healthcare projects, the news feed provides context on how Halberd’s research programs, partnerships, and technology demonstrations evolve over time.
Halberd Corporation (OTC PINK:HALB) announced potential advancements in treating obesity linked to neurodegenerative diseases. Research indicates that inflammatory cytokines in the cerebrospinal fluid of neurodegenerative patients are present in individuals with obesity. Halberd's patent-pending extracorporeal treatment aims to extract these antigens, which could mitigate obesity-related health issues such as diabetes and heart disease. The company is collaborating with university partners to further this research. CEO William A. Hartman highlighted that existing medical literature informed this development.
Halberd Corporation (OTC PINK: HALB) and GTX Corp (OTC PINK: GTXO) have announced a collaboration aimed at developing treatments for Alzheimer's Disease, PTSD, and other neurological disorders. The partnership leverages both companies' technologies to enhance diagnostics and treatments for these prevalent diseases. Additionally, GTX will market Halberd's VitaShieldMaxTM Immune Support on its e-commerce platform. Halberd's Chairman highlighted the opportunity for breakthrough innovations in biomedical treatment via this strategic alliance.
Halberd Corporation (OTC PINK:HALB) has reported significant advancements in treatments for neurodegenerative diseases, including Alzheimer's, PTSD, and CTE. The company has successfully eliminated Phosphorylated Tau from cerebral spinal fluid, a key contributor to Alzheimer's-related cognitive decline. They also eliminated E.coli from buffer solutions, targeting meningitis and sepsis. Despite laboratory successes, supply shortages have caused research delays. Halberd plans to apply for an up-listing to OTCQB, contingent upon audit approval, while continuing to strengthen its intellectual property portfolio.
Halberd Corporation (OTC PINK:HALB) announced that its VitaShieldMax™ immune support product is now available on Amazon, enhancing its accessibility alongside its website. CEO William A. Hartman expressed optimism, highlighting the product's formulation based on extensive medical research. Halberd holds exclusive rights to several patented COVID-19 treatments and is compliant with OTC Market regulations. However, the company cautions investors about the uncertainties related to COVID-19, acknowledging potential impacts on operations and financial performance.
Halberd Corp. and heliosDx have entered into a Scientific Collaboration Agreement aimed at developing new diagnostic technologies for effective disease management. This partnership, driven by Halberd's Chief Medical Officer, Dr. Patricio F. Reyes, focuses on improving diagnostic methods for neurological disorders and COVID-19. The collaboration is expected to enhance sample collection and processing, providing significant clinical outcomes and the potential for insurance reimbursement through CPT codes. Both companies are optimistic about the project's success and its impact on patient care.
Halberd Corporation (OTC PINK:HALB) has announced a breakthrough in laboratory testing, successfully eradicating the primary building block of neurofibrillary tangles associated with Alzheimer's Disease. Utilizing a patented extracorporeal process combined with a patent-pending laser technique, tests performed at Youngstown State University achieved near-total elimination of the Phosphorylated Tau antigen. This achievement paves the way for further studies and potential collaborations, particularly with military and sports organizations, to combat neurodegenerative diseases.
Halberd Corporation (OTC PINK:HALB) announced the appointment of Anthony Mirabelli as Vice-President of Mergers & Acquisitions. Mirabelli brings over 30 years of experience in the bio-pharmaceutical sector, focusing on product development, P&L management, and regulatory affairs. His expertise is expected to aid Halberd's R&D efforts in developing treatments for PTSD and Alzheimer's Disease. Halberd holds exclusive rights to multiple medical patents, including treatments for COVID-19. The company is in compliance with OTC Market reporting requirements.
Halberd Corp (OTC PINK:HALB) announced significant progress in its Alzheimer's Disease research conducted at Youngstown State University and Arizona State University. The company reported promising results from experiments on Phosphorylated Tau, a key protein linked to Alzheimer's. Following these findings, Halberd plans to conduct further replication tests and publish scientific findings. The company also noted successful results from tests on E. Coli. Halberd holds exclusive rights to several patents for extracorporeal treatments targeting various diseases, including COVID-19.
Halberd Corporation (OTC PINK:HALB) announced a Notice of Allowance for a patent from the US Patent Office for treating Cockayne Syndrome, a rare neurodegenerative disorder. This patent could pioneer methods to slow aging and strengthen Halberd's intellectual property in developing treatments for various diseases, including PTSD and Alzheimer's. The granted patent may allow control over Death-Associated Protein 1 (DAP1) levels, potentially reducing premature deaths. The CEO emphasized the company's strategy to target major diseases lacking effective cures.
Halberd Corp. (OTC PINK:HALB) has filed a U.S. joint provisional patent application for a novel treatment for Alzheimer's Disease using extracorporeal radio frequency. Developed through research at Arizona State University and Youngstown State University, the technology uses radio frequency waves to target and eliminate Alzheimer's-related antigens from bodily fluids.
Dr. Mitchell S. Felder, CTO, highlighted the promising results of their testing, while William A. Hartman, CEO, emphasized the reduced side effects associated with this treatment approach.